Patterns of tocilizumab use in clinical practice of rheumatoid arthritis: a multi-center, non-interventional study in China
10.3760/cma.j.cn141217-20191205-00409
- VernacularTitle:托珠单抗在类风湿关节炎临床实践中的用药模式：一项多中心非干预性研究
- Author:
Lijun WU
1
;
Lingli DONG
;
Yasong LI
;
Changhong XIAO
;
Xiaofei SHI
;
Yan ZHANG
;
Qin LI
;
Yi ZHAO
;
Bin ZHOU
;
Yongfei FANG
;
Lie DAI
;
Zhizhong YE
;
Yi ZHOU
;
Shitong WEI
;
Jianping LIU
;
Juan LI
;
Guixiu SHI
;
Lingyun SUN
;
Yaohong ZOU
;
Jingyang LI
;
Hongbin LI
;
Xiangyuan LIU
;
Fengchun ZHANG
Author Information
1. 新疆维吾尔自治区人民医院风湿免疫科，乌鲁木齐 830001
- From:
Chinese Journal of Rheumatology
2020;24(4):234-239
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the patterns of tocilizumab (TCZ) use, its efficacy and safety in patients with rheumatoid arthritis (RA) in routine clinical practice.Methods:A total of 407 patients with RA were enrolled from 23 centers and treated with TCZ within 8 weeks prior to the enrollment visit, and were followed for 6-month. The patterns of TCZ treatment at 6 months, the effectiveness and safety outcomes were recorded. Statistical analysis was performed using SAS version 9.4.Results:A total of 396 patients were included for analysis, in which 330 (83.3%) patients received TCZ combined with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), and 16.7%(66/396) received TCZ monotherapy. At baseline, TCZ was initiated in 56.6%(224/396) and 9.6%(38/396) of patients after failure of DMARDs and other biological agents (bDMARDs) respectively. During the 6-month follow-up period, the mean frequency of TCZ administration was (3.7±1.6), the mean TCZ dosage was (7.4±1.2) mg/kg, and the mean interval between doses was (40±13) days. 120(25.8%) patients were on TCZ treatment at the end of the study. Improvements in disease activity, systemic symptoms and patient report outcomes were observed at the end of the study. 22.7%(90/396) patients experienced at least one treatment related adverse event, and 8 patients experienced at least one serious adverse event.Conclusion:This study demonstrates that TCZ treatment is effective in patients with RA when being treated for 6 months with an acceptable safety profile. The duration of TCZ treatment needs to be extended.
